奈克塔制药
NKTR
35.78
-1.94
-5.14%
奈克塔制药
US · NKTR
#3017 按市值排名
上市于 1970
35.78
-1.94
-5.14%
实时 - 追踪5344个代码 - 心跳于1秒前
· 2026-10-16 20:02
✦ 量化股权信号 计算方式说明
增持
- 最近一期（2026/Q3）披露持股的机构数量增加了1家。
- 机构持股总比例上升了0.9个百分点。
机构持股
- 机构持股比例
- 106.77% +0.87pp
- 机构数量
- 267 +1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund51.39%
Hedge Fund42.60%
Public Company4.98%
VC/PE Fund4.15%
Private Company2.41%
Sovereign Wealth Fund0.64%
Government Pension Fund0.41%
Individual/Insider0.37%
Insurance Company0.16%
主要股东 截至 2026-06-30
FMR
14.84% · 5.07M 股
Two Seas Capital LP
9.80% · 3.35M 股
BlackRock
8.62% · 2.94M 股
BVF Partners L.P.
7.00% · 2.39M 股
Vanguard Capital Management, LLC
5.09% · 1.74M 股
Two Sigma Investments, LP
3.52% · 1.20M 股
Vestal Point Capital, LP
2.93% · 1.00M 股
State Street Global Advisors
2.66% · 909.68K 股
Geode Capital Management, LLC
2.58% · 881.31K 股
Morgan Stanley
2.41% · 824.20K 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 27次买入 · 23次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Howard Robin | Chief Executive Officer | 0.16% |
| R. Greer | Independent Director | 0.06% |
| Roy Whitfield | Lead Independent Director | 0.06% |
| Robert Chess | Independent Chairperson | 0.05% |
| Jonathan Zalevsky | Senior VP & Chief Research and Development Officer | 0.03% |
| Jeffrey Ajer | Independent Director | 0.01% |
| Diana Brainard | Independent Director | 0.01% |
| Mark Wilson | Chief Legal Officer | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-22 | Robert Chess | Independent Chairperson | Other Acquisition | +2,000 | -- |
| 2026-09-22 | Robert Chess | Independent Chairperson | Other Derivative Acquisition | +4,000 | $57.66 |
| 2026-09-22 | R. Greer | Independent Director | Other Acquisition | +2,000 | -- |
| 2026-09-22 | R. Greer | Independent Director | Other Derivative Acquisition | +4,000 | $57.66 |
| 2026-09-22 | Roy Whitfield | Lead Independent Director | Other Acquisition | +2,000 | -- |
| 2026-09-22 | Roy Whitfield | Lead Independent Director | Other Derivative Acquisition | +4,000 | $57.66 |
| 2026-09-22 | Jeffrey Ajer | Independent Director | Other Acquisition | +2,000 | -- |
| 2026-09-22 | Jeffrey Ajer | Independent Director | Other Derivative Acquisition | +4,000 | $57.66 |
| 2026-09-22 | Diana Brainard | Independent Director | Other Acquisition | +2,000 | -- |
| 2026-09-22 | Diana Brainard | Independent Director | Other Derivative Acquisition | +4,000 | $57.66 |
| 2026-08-17 | Howard Robin | Chief Executive Officer | Open Market Disposition | -418 | $71.98 |
| 2026-08-17 | Jonathan Zalevsky | Senior VP & Chief Research and Development Officer | Open Market Disposition | -186 | $71.98 |
| 2026-07-23 | Howard Robin | Chief Executive Officer | Other Derivative Acquisition | +57,200 | $15.15 |
| 2026-07-23 | Jonathan Zalevsky | Senior VP & Chief Research and Development Officer | Other Derivative Acquisition | +16,500 | $15.15 |
| 2026-06-29 | Jonathan Zalevsky | Senior VP & Chief Research and Development Officer | Automatic Disposition | -5,681 | $70.00 |
| 2026-06-16 | Howard Robin | Chief Executive Officer | Automatic Disposition | -20,000 | $59.97–61.65 |
| 2026-06-16 | Howard Robin | Chief Executive Officer | Intent to Sell (Form 144) | -10,000 | $60.27 |
| 2026-06-15 | Howard Robin | Chief Executive Officer | Intent to Sell (Form 144) | -10,000 | $60.96 |
| 2026-06-14 | Jonathan Zalevsky | Senior VP & Chief Research and Development Officer | Automatic Disposition | -5,538 | $60.71 |
| 2026-05-18 | Howard Robin | Chief Executive Officer | Open Market Disposition | -444 | $65.51 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:02:12 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
奈克塔制药 讨论区 0 条评论